Abstract
Topic - Recent Advances in Treatment of Alzheimer’s Disease by Sonam Patel, Nidhi Mishra and Dr Himani Awasthi (Guide)
Alzheimer’s disease is a neurodegenerative disorder that impairs mainly the memory and cognitive functions in elder people. Various studies conducted recently indicate that Alzheimer’s symptom-relieving drugs have the ability of regulating amyloid precursor protein processing and tau phosphorylation.
It has been proposed that ß-amyloid peptide has a key role in this disease. Several different pharmacological strategies have been developed with the aim of inhibiting the formation of ß-amyloid peptides, such as the inhibitors of ß-secretase and ?-secretase. In addition, anti-amyloid treatments have been developed, which include passive and active immunotherapies focused on inhibiting the aggregation of ß-amyloid peptides.
Advances in the identification of the molecular basis of AD can serve as a model to understand the causes of this neurodegenerative disease. However, the most recent clinical trials in 2 phase III trials with solanezumab, a humanised monoclonal antibody that promotes the clearance of ß-amyloid in the brain, indicate that this antibody does not show efficacy in patients with mild AD, suggesting that rethink this amyloidogenic hypothesis of AD.